WO2026068532A1 - Molécule de liaison bispécifique - Google Patents

Molécule de liaison bispécifique

Info

Publication number
WO2026068532A1
WO2026068532A1 PCT/EP2025/077334 EP2025077334W WO2026068532A1 WO 2026068532 A1 WO2026068532 A1 WO 2026068532A1 EP 2025077334 W EP2025077334 W EP 2025077334W WO 2026068532 A1 WO2026068532 A1 WO 2026068532A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
domain
binding molecule
amino acid
bispecific binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/077334
Other languages
English (en)
Inventor
Ronny FALK
Per-Ola Freskgård
Ken HONEK
Martin LARHAMMAR
Hanna LAUDON
Sebastian Meister
Lisa SANDERSJÖÖ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioarctic AB
Original Assignee
Bioarctic AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic AB filed Critical Bioarctic AB
Publication of WO2026068532A1 publication Critical patent/WO2026068532A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente divulgation concerne une molécule de liaison bispécifique qui se lie aux protofibrilles de bêta-amyloïde et au domaine de type protéase du récepteur 1 de la transferrine humaine (hTfR1), ainsi que ses utilisations thérapeutiques et diagnostiques.
PCT/EP2025/077334 2024-09-24 2025-09-24 Molécule de liaison bispécifique Pending WO2026068532A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP24202312.5 2024-09-24
EP24202312 2024-09-24

Publications (1)

Publication Number Publication Date
WO2026068532A1 true WO2026068532A1 (fr) 2026-04-02

Family

ID=92899886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/077334 Pending WO2026068532A1 (fr) 2024-09-24 2025-09-24 Molécule de liaison bispécifique

Country Status (1)

Country Link
WO (1) WO2026068532A1 (fr)

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003259A1 (fr) 1989-09-07 1991-03-21 Alkermes, Inc. Conjugues anticorps-agent neuropharmaceutique specifiques au recepteur de transferrine
WO2007108756A1 (fr) 2006-03-23 2007-09-27 Bioarctic Neuroscience Ab Anticorps améliorés sélectifs de protofibrilles et leur utilisation
WO2012075037A1 (fr) 2010-11-30 2012-06-07 Genentech, Inc. Anticorps anti-récepteur de la barrière hémato-encéphalique à faible affinité et leurs utilisations
WO2014033074A1 (fr) 2012-08-29 2014-03-06 F. Hoffmann-La Roche Ag Navette de la barrière hémato-encéphalique
WO2014189973A2 (fr) 2013-05-20 2014-11-27 Genentech, Inc. Anticorps anti-récepteur de transferrine et procédés d'utilisation
WO2016005466A2 (fr) 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab Anticorps se liant aux protofibrilles ass améliorés
WO2016081643A1 (fr) * 2014-11-19 2016-05-26 Genentech, Inc. Anticorps anti-récepteur de la transferrine et procédés d'utilisation
EP3088518A1 (fr) 2013-12-25 2016-11-02 JCR Pharmaceuticals Co., Ltd. Nouvel anticorps anti-récepteur de transferrine qui traverse la barrière hémato-encéphalique
WO2018011353A1 (fr) 2016-07-14 2018-01-18 Bioarctic Ab Protéine d'apport du cerveau
EP3315606A1 (fr) 2015-06-24 2018-05-02 JCR Pharmaceuticals Co., Ltd. Anticorps anti-récepteur de transferrine humaine passant au travers de la barrière hématoencéphalique
WO2018210898A1 (fr) * 2017-05-18 2018-11-22 F. Hoffmann-La Roche Ag Réduction de la réaction secondaire liée à l'administration d'un anticorps thérapeutique
EP3560958A1 (fr) 2016-12-26 2019-10-30 JCR Pharmaceuticals Co., Ltd. Nouvel anticorps anti-récepteur de la transferrine humaine capable de pénétrer dans la barrière hémato-encéphalique
US20200055931A1 (en) * 2015-06-24 2020-02-20 Hoffmann-La Roche Inc. Anti-transferrin receptor antibodies with tailored affinity
WO2022258841A1 (fr) 2021-06-11 2022-12-15 Bioarctic Ab Molécule de liaison bispécifique

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003259A1 (fr) 1989-09-07 1991-03-21 Alkermes, Inc. Conjugues anticorps-agent neuropharmaceutique specifiques au recepteur de transferrine
WO2007108756A1 (fr) 2006-03-23 2007-09-27 Bioarctic Neuroscience Ab Anticorps améliorés sélectifs de protofibrilles et leur utilisation
WO2012075037A1 (fr) 2010-11-30 2012-06-07 Genentech, Inc. Anticorps anti-récepteur de la barrière hémato-encéphalique à faible affinité et leurs utilisations
WO2014033074A1 (fr) 2012-08-29 2014-03-06 F. Hoffmann-La Roche Ag Navette de la barrière hémato-encéphalique
WO2014189973A2 (fr) 2013-05-20 2014-11-27 Genentech, Inc. Anticorps anti-récepteur de transferrine et procédés d'utilisation
EP3088518A1 (fr) 2013-12-25 2016-11-02 JCR Pharmaceuticals Co., Ltd. Nouvel anticorps anti-récepteur de transferrine qui traverse la barrière hémato-encéphalique
WO2016005466A2 (fr) 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab Anticorps se liant aux protofibrilles ass améliorés
WO2016081643A1 (fr) * 2014-11-19 2016-05-26 Genentech, Inc. Anticorps anti-récepteur de la transferrine et procédés d'utilisation
EP3315606A1 (fr) 2015-06-24 2018-05-02 JCR Pharmaceuticals Co., Ltd. Anticorps anti-récepteur de transferrine humaine passant au travers de la barrière hématoencéphalique
US20200055931A1 (en) * 2015-06-24 2020-02-20 Hoffmann-La Roche Inc. Anti-transferrin receptor antibodies with tailored affinity
WO2018011353A1 (fr) 2016-07-14 2018-01-18 Bioarctic Ab Protéine d'apport du cerveau
EP3560958A1 (fr) 2016-12-26 2019-10-30 JCR Pharmaceuticals Co., Ltd. Nouvel anticorps anti-récepteur de la transferrine humaine capable de pénétrer dans la barrière hémato-encéphalique
WO2018210898A1 (fr) * 2017-05-18 2018-11-22 F. Hoffmann-La Roche Ag Réduction de la réaction secondaire liée à l'administration d'un anticorps thérapeutique
WO2022258841A1 (fr) 2021-06-11 2022-12-15 Bioarctic Ab Molécule de liaison bispécifique

Non-Patent Citations (32)

* Cited by examiner, † Cited by third party
Title
AUSTERBERRY ET AL., EUR J PHARM BIOPHARM, vol. 115, 2017, pages 18 - 30
BOADO ET AL., BIOTECHNOL BIOENG, vol. 102, 2009, pages 1251 - 1258
BRAGA ET AL., CLIN CHIM ACTA, vol. 431, 2014, pages 143 - 147
BRYSON ET AL., BIODRUGS, vol. 24, no. 1, 2010, pages 1 - 8
COHEN-DVASHI ET AL., NAT COMMUN, vol. 11, 2020, pages 67
COUCH ET AL., SCI TRANSL MED, vol. 5, 2013, pages 183 - 57
COUCH JESSICA A ET AL: "Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier", SCIENCE TRANSLATIONAL MEDICINE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE (A A A S), US, vol. 5, no. 183, 1 May 2013 (2013-05-01), pages - 64, XP008163922, ISSN: 1946-6242, DOI: 10.1126/SCITRANSLMED.3005338 *
DARLINGBRAULT, ASSAY AND DRUG DEV TECH, vol. 2, no. 6, 2004, pages 647 - 657
FRESKGARDURICH, NEUROPHARMACOLOGY, vol. 120, 2017, pages 38 - 55
GUSTAVSSON ET AL., ALZHEIMER'S DEMENT, vol. 19, 2023, pages 658 - 670
HOLLAND ET AL., J CLIN IMMUNOL, vol. 33, 2013, pages 1192 - 1203
HYMAN ET AL., N ENGL J MED, vol. 311, 1984, pages 214 - 218
JOHANSSON ET AL., MABS, vol. 15, no. 1, 2023, pages 2215887
KABAT: "NIH Publication no 91-3242", 1991, US DEPARTMENT OF HEALTH AND HUMAN SERVICES, article "Sequences of Proteins of Immunological Interest"
KABSCH, ACTA CRYSTALLOGR D BIOL CRYSTALLOGR, vol. 66, 2010, pages 125 - 132
KOVACS-NOLANMINE, BIOCHIM BIOPHYS ACTA, vol. 1760, 2006, pages 1884 - 1893
LAWRENCE ET AL., SCIENCE, vol. 286, 1999, pages 779 - 782
LI ET AL., PROC NATL ACAD SCI, vol. 107, no. 8, 2010, pages 3505 - 10
LIU ET AL., MABS, vol. 14, no. 1, 2022, pages 2073632
MAIER ET AL., MOL THER NUCLEIC ACIDS, vol. 5, 2016, pages 321
MONTEMIGLIO ET AL., NAT COMMUN, vol. 10, 2019, pages 1121
NIEBA ET AL., PROT ENG, vol. 10, no. 4, 1997, pages 435 - 444
NIEWOEHNER JENS ET AL: "Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle", NEURON, ELSEVIER, AMSTERDAM, NL, vol. 81, no. 1, 8 January 2014 (2014-01-08), pages 49 - 60, XP028813101, ISSN: 0896-6273, DOI: 10.1016/J.NEURON.2013.10.061 *
PARDRIDGE WILLIAM M.: "Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier", vol. 3, 15 August 2023 (2023-08-15), XP093100061, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426772/pdf/nihms-1916027.pdf> DOI: 10.3389/fddev.2023.1227816 *
ROFO FADI ET AL: "A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer's Disease Mice", vol. 19, no. 5, 8 August 2022 (2022-08-08), Cham, pages 1588 - 1602, XP093047165, ISSN: 1933-7213, Retrieved from the Internet <URL:https://link.springer.com/article/10.1007/s13311-022-01283-y/fulltext.html> DOI: 10.1007/s13311-022-01283-y *
STANIMIROVIC ET AL., BIODRUGS, vol. 32, 2018, pages 547 - 559
SYV�NEN STINA ET AL: "Efficient clearance of A[beta] protofibrils in A[beta]PP-transgenic mice treated with a brain-penetrating bifunctional antibody", ALZHEIMER'S RESEARCH & THERAPY, vol. 10, no. 1, 24 December 2018 (2018-12-24), XP055877665, DOI: 10.1186/s13195-018-0377-8 *
WANG ET AL., J PHARM SCI, vol. 96, 2007, pages 1 - 26
WEKSLER ET AL., FLUIDS BARRIERS CNS, vol. 10, 2013, pages 16
WILLUDA ET AL., CANCER RES, vol. 59, 1999, pages 5758 - 67
WORNPLUCKTHUN, J MOL BIOL, vol. 305, no. 5, 2001, pages 989 - 1010
YU ET AL., SCI TRANSL MED, vol. 6, 2014, pages 261 - 154

Similar Documents

Publication Publication Date Title
CN107847595B (zh) 特异性针对过度磷酸化τ蛋白的抗体及其使用方法
WO2018161872A1 (fr) Anticorps anti-b7-h3, fragment de liaison à l&#39;antigène de celui-ci, et utilisation pharmaceutique associée
AU2015350190A1 (en) CD47 antibodies, methods, and uses
WO2022258841A1 (fr) Molécule de liaison bispécifique
US12559548B2 (en) Antibodies to misfolded TDP-43 and methods of use
IL323276A (en) Antibody that binds to the protease-like domain of the human transferrin receptor htfr1
CA3242070A1 (fr) Anticorps reconnaissant la sortiline
IL273202B1 (en) Binding proteins to the human thrombin receptor, par4
WO2026068532A1 (fr) Molécule de liaison bispécifique
US20250388664A1 (en) Bispecific binding molecule
US20260035475A1 (en) Stabilized binding molecule
WO2026068513A1 (fr) Molécule de liaison bispécifique
WO2026068519A1 (fr) Molécule de liaison sensible au ph
CA3169838A1 (fr) Anticorps contre klk5
TW202607032A (zh) 雙特異性結合分子
JP7735545B2 (ja) Ｃｄｃプラットホーム抗体
RU2846901C1 (ru) Антитело против trop-2, его антигенсвязывающий фрагмент или его мутант и его медицинское применение
JP7851924B2 (ja) 抗ｔｒｏｐ－２抗体、その抗原結合断片又はその変異体、及びそれらの医学的使用
JPWO2019054460A1 (ja) 抗ｒａｍｐ２抗体
WO2025229206A1 (fr) Molécules de liaison monovalentes anti-iga et procédés d&#39;utilisation
HK40119405A (en) Binding proteins to the human thrombin receptor, par4
CA3194725A1 (fr) Anticorps anti-trop-2, fragment de liaison a l&#39;antigene de celui-ci ou mutant de celui-ci, et utilisation medicale associee
HK40110366A (zh) 半乳凝素-10抗体